CIRM Funded Clinical Trials
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors
Robert Lowsky
Disease Area:
Investigator:
Institution:
CIRM Grant:
Award Value:
$6,653,266
Trial Sponsor:
Stanford University
Trial Stage:
Phase 1
Trial Status:
Active, not recruiting
Targeted Enrollment:
15
ClinicalTrials.gov ID:
Details:
Stanford scientists are working with kidney transplant patients to see if injecting blood stem cells and T cells (which play an important role in the immune system) from the kidney donor into the kidney recipient can enable the recipient to bypass the need for a life-long dependence on immunosuppressant drugs which have numerous negative side effects.
Design:
Open label, single arm study.
Goal:
Primary: Safety. Secondary: Preliminary efficacy.
